US 11,938,183 B2
Autoimmune antibodies for use in inhibiting cancer cell growth
Andrew J. Ewald, Catonsville, MD (US); Veena Padmanaban, Baltimore, MD (US); Livia Casciola-Rosen, Pikesville, MD (US); and Antony Rosen, Pikesville, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US)
Filed by The Johns Hopkins University, Baltimore, MD (US)
Filed on Jul. 2, 2021, as Appl. No. 17/366,635.
Application 17/366,635 is a continuation of application No. 15/573,323, abandoned, previously published as PCT/US2016/031827, filed on May 11, 2016.
Claims priority of provisional application 62/159,696, filed on May 11, 2015.
Prior Publication US 2022/0160868 A1, May 26, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/06 (2006.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); G01N 33/50 (2006.01); G01N 33/564 (2006.01); G01N 33/574 (2006.01); C07K 16/40 (2006.01)
CPC A61K 39/395 (2013.01) [C07K 16/06 (2013.01); C07K 16/18 (2013.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); G01N 33/5011 (2013.01); G01N 33/5029 (2013.01); G01N 33/564 (2013.01); G01N 33/574 (2013.01); A61K 2039/505 (2013.01); C07K 16/40 (2013.01)] 17 Claims
 
1. A method for identifying one or more antibodies that inhibit a cancer cell in vitro, the method comprising:
isolating blood from a subject afflicted with scleroderma;
purifying the one or more antibodies from the blood;
assaying in vitro the growth, viability, or mobility of a cancer cell in the presence of the one or more antibodies, wherein a reduction in the growth, viability, or mobility of the cancer cell in the presence of the one or more antibodies, as compared to the growth, viability or mobility of the cancer cell in the absence of the one or more antibodies, identifies the one or more antibodies as inhibiting the cancer cell;
wherein the subject afflicted with scleroderma is not afflicted with cancer; and
wherein the growth, viability, or mobility of the cancer cell is reduced to a greater degree than would be observed when the cancer cell is assayed in the presence of a reference antibody obtained from a reference subject that is afflicted with scleroderma, wherein the reference subject is afflicted with cancer.